Brainstorm Cell (BCLI): יחס חוב לטווח קצר להון עצמי
Brainstorm Cell (BCLI) is actively developing protocols for NurOwn therapy aimed at combating ALS, currently undergoing the regulatory approval stage. The business relies on synergy with specialized research centers to restore brain functions. Meanwhile, the R&D model is based on outsourced testing, and the indicator stands at 0.00. The financial price chart below demonstrates the dynamics of the company's debt and equity.
פילוחים אנליטיים של חברת brainstorm-cell.com (BCLI)
The stability of Brainstorm Cell (BCLI) depends on the seamless operation of costly cryogenic logistics, which requires high liquidity to minimize supply chain disruption risks. This metric compares the volume of short-term borrowings against equity, determining the business's degree of dependence on external refinancing and its level of financial autonomy. By analyzing changes in the ratio of current liabilities to equity, an investor assesses the company's resilience to creditor pressure and the risk of bankruptcy.